Current Review of Pain

, Volume 4, Issue 2, pp 148–157 | Cite as

Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome

  • Laurence A. Bradley
  • Nancy L. McKendree-Smith
  • Graciela S. Alarcón
Article

Abstract

Individuals with fibromyalgia (FM) and/or chronic fatigue syndrome (CFS) report arthralgias and myalgias. However, only persons with FM alone exhibit abnormal pain responses to mild levels of stimulation, or allodynia. We identify the abnormalities in the neuroendocrine axes that are common to FM and CFS as well as the abnormalities in central neuropeptide levels and functional brain activity that differentiate these disorders. These two sets of factors, respectively, may account for the similiarities and differences in the pain experiences of persons with FM and CFS.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Demitrack MA: Chronic fatigue syndrome and fibromyalgia: dilemmas in diagnosis and clinical management. Psych Clin North Am 1998, 21:671–697. Provides a cogent review of the classification criteria for FM and CFS as well as the literature on neuroendocrine function in these disorders. It also includes valuable guidelines for the management of patients with FM and CFS.CrossRefGoogle Scholar
  2. 2.
    Jason LA, Richman JA, Rademaker AW, et al.: A communitybased study of chronic fatigue syndrome. Arch Intern Med 1999, 159:2129–2137.CrossRefPubMedGoogle Scholar
  3. 3.
    Buchwald D: Fibromyalgia and chronic fatigue syndrome: similarities and differences. Rheum Dis Clin North Am 1996, 22:219–243.CrossRefPubMedGoogle Scholar
  4. 4.
    Goldenberg DL, Simms RW, Geiger A, Komaroff AL: High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum 1990, 33:381–387.CrossRefPubMedGoogle Scholar
  5. 5.
    Wolfe F, Ross K, Anderson J, et al.: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19–28.CrossRefPubMedGoogle Scholar
  6. 6.
    White KC, Speechly M, Ostliye T: The London fibromyalgia epidemiology study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999, 26:1570–1576.PubMedGoogle Scholar
  7. 7.
    Buchwald D, Umali P, Umali J, et al.: Chronic fatigue and the chronic fatigue syndrome: prevalence of chronic fatigue and chronic fatigue syndrome in a Pacific Northwest health care system. Ann Intern Med 1995, 123:81–88.CrossRefPubMedGoogle Scholar
  8. 8.
    Jason LA, Taylor R, Wagner L, et al.: Estimating rates of chronic fatigue syndrome from a community based sample: a pilot study. Am J Community Psychol 1995, 23:557–568.CrossRefPubMedGoogle Scholar
  9. 9.
    Steele L, Dobbins JG, Fukuda K, et al.: The epidemiology of chronic fatigue in San Francisco. Am J Med 1998, 105(suppl):83S-90S.CrossRefPubMedGoogle Scholar
  10. 10.
    Fukuda K, Straus SE, Hickie I, et al.: The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994, 121:953–959.CrossRefPubMedGoogle Scholar
  11. 11.
    Buchwald D, Garrity DL: Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 154:2049-2053.Google Scholar
  12. 12.
    Wysenbeek AJ, Shapira Y, Leibovici L: Primary fibromyalgia and the chronic fatigue syndrome. Rheumatol Int 1991, 10:227–229.CrossRefPubMedGoogle Scholar
  13. 13.
    Norregard J, Bulow PM, Prescott E, et al.: A 4 year follow-up study in fibromyalgia. Relationship to chronic fatigue syndrome. Scand J Rheumatol 1993, 22:35–38.CrossRefGoogle Scholar
  14. 14.
    Gibson JJ, Littlejohn G, Gorman MM, et al.: Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain 1994, 58:185–193.CrossRefPubMedGoogle Scholar
  15. 15.
    Aaron LA, Bradley LA, Alarcón GS, et al.: Psychiatric diagnoses in patients with fibromyalgia are related to health careseeking behavior rather than to illness. Arthritis Rheum 1996, 39:436–445.CrossRefPubMedGoogle Scholar
  16. 16.
    Clauw DJ, Chrousos GP: Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997, 4:134–153.PubMedGoogle Scholar
  17. 17.
    Pellegrino MJ, Waylonis GW, Sommer A: Familial occurrence of primary fibromyalgia. Arch Phys Rehabil 1989, 70:61–63.Google Scholar
  18. 18.
    Buskila D, Neumann L, Hazanov I, Carmi R: Familial aggregation in the fibromyalgia syndrome. Sem Arthritis Rheum 1996, 26:605–611.CrossRefGoogle Scholar
  19. 19.
    Buskila D, Neumann L: Fibromyalgia (FM) syndrome and nonarticular tenderness in relatives of patients with FM. J Rheumatol 1997, 24:941–944.PubMedGoogle Scholar
  20. 20.
    Yunus MB, Khan MA, Rawlings KK, et al.: Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999, 26:408–412.PubMedGoogle Scholar
  21. 21.
    Offenbaecher M, Bondy B, de Jonge S, et al.: Possible association of fibromyalgia with polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999, 42:2482–2488.CrossRefPubMedGoogle Scholar
  22. 22.
    Mogil JS, Richards SP, O’Toole LA, et al.: Genetic sensitivity to hot-plate nocioception in DBA/2J and C57BL/6J inbred mouse strains: possible sex-specific mediation by delta2-opiod receptors. Pain 1997, 70:267–277.CrossRefPubMedGoogle Scholar
  23. 23.
    Elmer GI, Pieper JO, Negus SS, Woods JH: Genetic variance in nocioception and its relationship to the potency of morphine-induced analgesia in thermal and chemical tests. Pain 1998, 75:129–140.CrossRefPubMedGoogle Scholar
  24. 24.
    Crofford LJ, Pillemer SR, Kalogeras KT, et al.: Hypothalamicpituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994, 37:1583–1592.CrossRefPubMedGoogle Scholar
  25. 25.
    Crofford LJ, Demitrack MA: Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 1996, 22:267–284.CrossRefPubMedGoogle Scholar
  26. 26.
    McCain GA, Tilbe KS: Diurnal hormonal variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol 1989, 16:154–157.Google Scholar
  27. 27.
    Demitrack MA, Dale JK, Straus SE, et al.: Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991, 73:1224–1234.CrossRefPubMedGoogle Scholar
  28. 28.
    Martinez-Lavín M, Hermosillo AG, Mendoza C, et al.: Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997, 24:714–718.PubMedGoogle Scholar
  29. 29.
    Adler GK, Kinsley BT, Hurwitz S, et al.: Reduced hypothalamicpituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999, 106:534–543.CrossRefPubMedGoogle Scholar
  30. 30.
    Lariviere WR, Melzack R: The role of corticotrophin-releasing factor in pain and analgesia. Pain 2000, 84:1–12.CrossRefPubMedGoogle Scholar
  31. 31.
    Chrousos GP, Gold PW: The concepts of stress and stress symptom disorders. Overview of physical and behavioral homeostasis. JAMA 1992, 267:1244–1252.CrossRefPubMedGoogle Scholar
  32. 32.
    Bennett RM, Clark S, Campbell SM, Burckhardt CS: Low levels of somatomedin C in patients with the fibromyalgia syndrome: a possible link between sleep and muscle pain. Arthritis Rheum 1992, 35:1113–1116.CrossRefPubMedGoogle Scholar
  33. 33.
    Moldofsky H, Scarisbrick P, England R, et al.: Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis” syndrome and healthy subjects. Psychosom Med 1975, 37:341–351.CrossRefPubMedGoogle Scholar
  34. 34.
    Griep EN, Boersma JW, Kloet ER: Pituitary release of growth hormone and prolactin in the primary fibromyalgia syndrome. J Rheumatol 1994, 21:2125–2130.PubMedGoogle Scholar
  35. 35.
    Bennett RM, Cook DM, Clark SR, et al.: Hypothalamicpituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalagia. J Rheumatol 1997, 24:1384–1389.PubMedGoogle Scholar
  36. 36.
    Ferraccioli G, Guerra P, Rizzi V, et al.: Somatomedin C (insulinlike growth factor 1) levels decrease during acute changes of stress-related hormones. Relevance for fibromyalgia. J Rheumatol 1994, 21:1332–1334.PubMedGoogle Scholar
  37. 37.
    Russell IJ, Vipraio GA, Michalek JE, Lopez YG: Insulin-like growth factor in fibromyalgia, rheumatoid arthritis, osteoarthritis, and healthy normal controls: roles of diagnosis, age, sex, and ethnic origin [abstract]. Arthritis Rheum 1992, 35:B263.CrossRefGoogle Scholar
  38. 38.
    Bennett RM, Clark SR, Walczk: A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998, 104:227–231.CrossRefPubMedGoogle Scholar
  39. 39.
    Bennett AL, Mayes DM, Fagioli LR, et al.: Somatomedin C (insulin-like growth factor 1) levels in patients with chronic fatigue syndrome. J Psychiatr Res 1997, 31:91–96.CrossRefPubMedGoogle Scholar
  40. 40.
    Allain TJ, Bearn JA, Coskeran P, et al.: Changes in growth hormone, insulin, insulin-like growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. Biol Psychiatry 1997, 41:567–573.CrossRefPubMedGoogle Scholar
  41. 41.
    Buchwald D, Umall J, Stene M: Insulin-like growth factor-1 (somatomedin C) levels in chronic fatigue syndrome and fibromyalgia. J Rheumatol 1996, 23:739–742.PubMedGoogle Scholar
  42. 42.
    Krieger DT, Rizzo F: Serotonin mediation of circadian periodicity of plasma 17-hydroxycorticosteroids. Am J Physiol 1969, 217:1703–1707.PubMedGoogle Scholar
  43. 43.
    Holmes MC, DiRenzy G, Gillham B, et al.: Role of serotonin in the control of secretion of corticotrophin releasing factor. J Endocrinol 1982, 93:151–160.CrossRefPubMedGoogle Scholar
  44. 44.
    Russell IJ, Michalek JE, Vipraio GA, et al.: Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992, 19:104–109.PubMedGoogle Scholar
  45. 45.
    Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550–556.CrossRefPubMedGoogle Scholar
  46. 46.
    Wolf F, Russell IJ, Vipraio GA, et al.: Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 1997, 24:555–559.Google Scholar
  47. 47.
    Yunus MB, Dailey JW, Aldag JC, et al.: Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992, 19:90–94.PubMedGoogle Scholar
  48. 48.
    Houvenagel E, Forzy G, Cortet B, Vincent G: 5 hydroxyindoleacetic acid in cerebrospinal fluid in fibromyalgia. Arthritis Rheum 1990, 99(suppl 33):S55.Google Scholar
  49. 49.
    Demitrack MA, Gold PW, Dale JK, et al.: Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol Psychiatry 1992, 32:1065–1077.CrossRefPubMedGoogle Scholar
  50. 50.
    Bakheit AMO, Behan PO, Dinan TG, et al.: Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ 1992, 304:1010–1012.CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Vaerøy H, Helle R, Forre Ø, et al.: Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21–26.CrossRefPubMedGoogle Scholar
  52. 52.
    Russell IJ, Orr MD, Littman B, et al.: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593–1601.CrossRefPubMedGoogle Scholar
  53. 53.
    Bradley LA, Sotolongo A, Alberts KR, et al.: Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. J Musculoskeletal Pain 1999, 7:285–292. Describes our methods for studying biological and psychosocial factors in patients and nonpatients with FM. Our data generally show that similar abnormalities in CSF levels of substance P and functional brain activity are found in patients and nonpatients, indicating that they are independent of the differences between these groups in psychological distress.CrossRefGoogle Scholar
  54. 54.
    Evengard B, Nilsson CG, Lindh G, et al.: Chronic fatigue syndrome differs fromfibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 1998, 78:153–155.CrossRefPubMedGoogle Scholar
  55. 55.
    Vaeroy H, Sakurda T, Forre O, et al.: Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain-related neuropeptides with special reference to calcitonin gene-related peptide (CGRP). J Rheumatol 1989, 19:94–97.Google Scholar
  56. 56.
    Vaeroy H, Nyberg F, Terenius L: No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and Met-enkephalin-Arg6-Phe7. Pain 1991, 46:139–143.CrossRefPubMedGoogle Scholar
  57. 57.
    Pillemer SR, Bradley LA, Crofford LJ, et al.: The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997, 40:1928–1937.CrossRefPubMedGoogle Scholar
  58. 58.
    Kosek E, Ekholm J, Hansson P: Sensory dysfunction in fibromyalgia patients with implcations for pathogenic mechanisms. Pain 1996, 68:375–383.CrossRefPubMedGoogle Scholar
  59. 59.
    Bendsten L, Norregaard J, Jensen R, Olesen J: Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis Rheum 1997, 40:98–102.CrossRefGoogle Scholar
  60. 60.
    Missole C, Toroni F, Sigala S, et al.: Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Proc Natl Acad Sci U S A 1996, 93:4240–4245.CrossRefGoogle Scholar
  61. 61.
    Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564–1569.PubMedGoogle Scholar
  62. 62.
    Lindsay RM, Lockett C, Sternberg J, Winter J: Neuropeptide expression in cultures of adult sensory neurons: modulation of substance P and calcitonin gene-related peptide levels by nerve growth factor. Neuroscience 1989, 33:53–65.CrossRefPubMedGoogle Scholar
  63. 63.
    Lange G, Wang S, DeLuca J, Natelson BH: Neuroimaging in chronic fatigue syndrome. Am J Med 1998, 105(suppl):50S-53S.CrossRefPubMedGoogle Scholar
  64. 64.
    Buchwald D, Cheney PR, Peterson DL, et al.: A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpes virus type 6 infection. Ann Intern Med 1992, 116:103–113.CrossRefPubMedGoogle Scholar
  65. 65.
    Natelson BH, Cohen JM, Brassloff I, Lee HJ: A controlled study of brain magnetic imaging in patients with the chronic fatigue syndrome. J Neurol Sci 1993, 120:213–217.CrossRefPubMedGoogle Scholar
  66. 66.
    Lange G, DeLuca J, Maldjian JA, et al.: Brain abnormalities exist in a subset of patients with chronic fatigue syndrome. J Neurol Sci 1999, 171:3–7.CrossRefPubMedGoogle Scholar
  67. 67.
    Schwartz RB, Garada BM, Komoroff AL, et al.: Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. Am J Roentgenol 1994, 162:935–941.CrossRefGoogle Scholar
  68. 68.
    Greco A, Tannock C, Brostoff J, Costa DC: Brain MR in chronic fatigue syndrome. AJNR Am J Neuroradiol 1997, 18:1265–1269.PubMedGoogle Scholar
  69. 69.
    Burton TM: Some doctors operate on people diagnosed with chronic fatigue. The Wall Street Journal, Nov 11, 1999:1–3.Google Scholar
  70. 70.
    Alarcón GS, Bradley LA, Hadley MN, et al.: Does Chiari malformation contribute to fibromyalgia symptoms? [abstract] Arthritis Rheum 1997, 40:S190.Google Scholar
  71. 71.
    Bradley LA, Alarcón GS: Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia? Arthritis Rheum 1999, 42:2731–2732.CrossRefPubMedGoogle Scholar
  72. 72.
    Mena I, Villanueva-Meyer J: Study of cerebral perfusion by NeuroSPECT in patients with chronic fatigue syndrome. In The Clinical and Scientific Basis of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome. Edited by Hyde BM et al. Ottawa: Nightingale Research Foundation; 1992:432–439.Google Scholar
  73. 73.
    Goldstein JA, Mena I, Jouanne E, Lesser I: The assessment of vascular abnormalities in late life chronic fatigue syndrome by brain SPECT: comparison with late life major depressive disorder. J Chronic Fatigue Syndrome 1995, 1:55–79.CrossRefGoogle Scholar
  74. 74.
    Ichise M, Salit IE, Abbey SE, et al.: Assessment of regional cerebral perfusion by 99mTcHMPAO SPECT in the chronic fatigue syndrome. Nucl Med Commun 1992, 13:767–772.CrossRefPubMedGoogle Scholar
  75. 75.
    Schwartz RB, Garada BM, Komaroff AL, et al.: SPECT imaging of the brain: comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression. AJR Am J Roentgenol 1994, 162:943–951.CrossRefPubMedGoogle Scholar
  76. 76.
    Costa DC, Tannock C, Brostoff J: Brainstem perfusion is impaired in chronic fatigue syndrome. Q J Med 1995, 88:767–773.Google Scholar
  77. 77.
    Tirelli U, Chierichetti F, Tavio M, et al.: Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med 1998, 105(suppl):54S-58S.CrossRefPubMedGoogle Scholar
  78. 78.
    Fischler B, D’Haenen H, Cluydts R, et al.: Comparison of 99mTcHMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow. Neuropsychobiology 1996, 34:174–183.CrossRefGoogle Scholar
  79. 79.
    Mountz JM, Bradley LA, Modell JG, et al.: Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995, 38:926–938.CrossRefPubMedGoogle Scholar
  80. 80.
    Iadarola MJ, Max MD, Berman KF, et al.: Unilateral decrease in thalamic activity observed with position emission tomography in patients with chronic neuropathic pain. Pain 1995, 63:55–64.CrossRefPubMedGoogle Scholar
  81. 81.
    Di Piero V, Jones AKP, Iannotti F, et al.: Chronic pain: a PET study of the central effects of percutaneous high cervical cordotomy. Pain 1991, 46:9–12.CrossRefPubMedGoogle Scholar
  82. 82.
    San Pedro EC, Mountz JM, Liu HG, et al.: Familial painful restless leg syndrome correlates with a pain-dependent variation of blood flow to the caudate nucleus, thalamus, and anterior cingulate gyrus. J Rheumatol 1998, 25:2270–2275.PubMedGoogle Scholar
  83. 83.
    Weigent DA, Bradley LA, Blalock JE, Alarcón GS: Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci 1998, 315:405–412. Provides a detailed description of our model of the etiopathogenesis of abnormal pain perception in persons with FM.CrossRefPubMedGoogle Scholar
  84. 84.
    Bradley LA, Sotolongo A, Alarcón GS, et al.: Dolorimeter stimulation elicits abnormal pain sensitivity and regional cerebral blood flow (rCBF) in the right cingulate cortex (CC) as well as passive coping strategies in non-depressed patients with fibromyalgia (FM) [abstract]. Arthritis Rheum 1999, 42:S342.CrossRefGoogle Scholar
  85. 85.
    Epstein SA, Kay G, Clauw D, et al.: Psychiatric disorders in patients with fibromyalgia: a multicenter investigation. Psychosomatics 1999, 40:57–63.CrossRefPubMedGoogle Scholar
  86. 86.
    Walker EA, Keegan D, Gardner G. et al.: Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability. Psychosom Med 1997, 59:565–571.CrossRefPubMedGoogle Scholar
  87. 87.
    Hudson JI, Hudson MS, Pliner LF, et al.: Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 1985, 142:441–446.CrossRefPubMedGoogle Scholar
  88. 88.
    Kirmayer LJ, Robbins JM, Kapsuta MA: Somatization and depression in fibromyalgia syndrome. Am J Psychiatry 1988, 145:950–954.CrossRefPubMedGoogle Scholar
  89. 89.
    Forslind K, Fredriksson E, Nived O: Does primary fibromyalgia really exist? Br J Rheumatol 1990, 29:368–370.CrossRefPubMedGoogle Scholar
  90. 90.
    Hudson JI, Pope HG: Fibromyalgia and psychopathology: is fibromyalgia a form of “affective spectrum disorder.” J Rheumatol 1989, 16:15–22.Google Scholar
  91. 91.
    Kersh BC, Bradley LA, Alarcón GS, et al.: Psychosocial and health status variables independently predict health care seeking in fibromyalgia: implications for a model of etiopathogenesis. Pain 2000, in press.Google Scholar
  92. 92.
    Aaron LA, Bradley LA, Alarcón GS, et al.: Perceived physical and emotional trauma as precipitating events in fibromyalgia: association with health care seeking and disability status but not pain severity. Arthritis Rheum 1997, 40:453–460.CrossRefPubMedGoogle Scholar
  93. 93.
    Bradley LA, Richter JE, Pulliam TJ et al.: The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. Am J Gastroenterol 1993, 88:11–19.PubMedGoogle Scholar
  94. 94.
    Melzack R: Gate control theory: on the evolution of pain concepts. Pain Forum 1996 5:125–128.Google Scholar
  95. 95.
    Loeser JD, Melzack R: Pain: an overview. Lancet 1999, 353:1607–1609.CrossRefPubMedGoogle Scholar
  96. 96.
    Bradley LA, Alberts KR: Psychological and behavioral approaches to pain management for patient with rheumatic disease. Rheum Dis Clin North Am 1999, 25:215–232.CrossRefPubMedGoogle Scholar
  97. 97.
    Bradley LA, Alarcón GS: 97. Bradley LA, Alarcón GS: Fibromyalgia. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 14. Edited by Koopman WJ. Baltimore, MD: Williams and Wilkins; 2000, in pressGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Laurence A. Bradley
    • 1
  • Nancy L. McKendree-Smith
    • 1
  • Graciela S. Alarcón
    • 1
  1. 1.Division of Clinical Immunology and RheumatologyUniversity of Alabama at Birmingham, School of MedicineBirminghamUSA

Personalised recommendations